3/14/2023 8:40:58 AM
Oragenics Announces Positive Results In Several Lantibiotics Compounds Against MRSA And VRE
3/1/2023 7:42:51 AM
Oragenics Enters Into License Agreement With Inspirevax To Develop Intranasal Covid Vaccine Candidate
2/3/2023 7:35:49 AM
Oragenics Says Regained Compliance With NYSE American's Continued
listing Standards
12/22/2022 7:33:19 AM
Oragenics Announces Favorable Toxicology Results For Its COVID-19 Intranasal Vaccine Candidate
8/24/2022 7:19:03 AM
OneWater Marine Reaches Agreement To Acquire Taylor Marine Centers
8/24/2022 7:04:25 AM
Oragenics Announces Favorable Preliminary Toxicology Data For Intranasal COVID-19 Vaccine Candidate
6/14/2022 7:35:14 AM
Oragenics Announces Publication Of Positive Data For NT-CoV2-1 Intranasal COVID-19 Vaccine Candidate
5/17/2022 7:47:28 AM
Oragenics Says Positioning NT-CoV2-1 To Compete In Later Phase Of COVID-19 Pandemic
3/22/2022 9:09:12 AM
Oragenics Initiates Pivotal IND-Enabling Toxicology Study On Its Intranasal COVID-19 Vaccine Candidate, NT-CoV2-1
3/3/2022 9:34:24 AM
Oragenics Reports Positive Data On Their Intranasal SARS-CoV-2 Vaccine Candidate In A Posted Preprint Manuscript
1/26/2022 7:36:34 AM
Oragenics Announces Adjournment Of Annual Meeting Of Shareholders Due To Lack Of Quorum
12/20/2021 8:13:21 AM
Oragenics Extends Collaboration With National Research Council Of Canada To Develop Vaccine Against Omicron Variant
12/1/2021 8:08:13 AM
Oragenics Announces Positive COVID-19 Study Results Evaluating Multiple Formulations Of SARS-CoV-2 Vaccine Candidate
10/4/2021 7:34:37 AM
Oragenics Awarded $250,000 Grant From NIGMS For The Continued Research And Development Of Lantibiotics